Local microRNA delivery targets Palladin and prevents metastatic breast cancer (Gilam & Conde et al. Nature Communications 2016)

Preventing breast cancer metastasis with a local platform for miRNA and drug delivery

Go to the profile of João Conde
Feb 22, 2017
0
0
Metastasis is the primary cause for mortality in breast cancer. MicroRNAs, gene expression master regulators, constitute an attractive candidate to control metastasis. Here we show that breast cancer metastasis can be prevented by miR-96 or miR-182 treatment, and decipher the mechanism of action. We found that miR-96/miR-182 downregulate Palladin protein levels, thereby reducing breast cancer cell migration and invasion. A common SNP, rs1071738, at the miR-96/miR-182-binding site within the Palladin 30-UTR abolishes miRNA:mRNA binding, thus diminishing Palladin regulation by these miRNAs. Regulation is successfully restored by applying complimentary miRNAs. A hydrogel-embedded, gold-nanoparticle-based delivery vehicle provides efficient local, selective, and sustained release of miR-96/miR-182, markedly suppressing metastasis in a breast cancer mouse model. Combined delivery of the miRNAs with a chemotherapy drug, cisplatin, enables significant primary tumour shrinkage and metastasis prevention. Our data corroborate the role of miRNAs in metastasis, and suggest miR-96/miR-182 delivery as a potentialanti-metastatic drug.

http://www.nature.com/articles/ncomms12868

Go to the profile of João Conde

João Conde

Marie Curie Early-Stage Career Fellow, MIT

Cancer Nanotechnology

No comments yet.